

Revision date: 08-Sep-2010 Version: 2.0 Page 1 of 7

### IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING

Pfizer Inc Pfizer Pharmaceuticals Group 235 East 42nd Street New York, New York 10017 1-212-573-2222

Emergency telephone number:
CHEMTREC (24 hours): 1-800-424-9300
Contact E-Mail: pfizer-MSDS@pfizer.com

Pfizer Ltd
Ramsgate Road
Sandwich, Kent
CT13 9NJ
United Kingdom
+00 44 (0)1304 616161
Emergency telephone number:

ChemSafe (24 hours): +44 (0)208 762 8322

Material Name: Clindamycin Phosphate Topical Gel

Trade Name: Cleocin T Chemical Family: Mixture

Intended Use: Pharmaceutical product used as antibiotic agent

### 2. HAZARDS IDENTIFICATION

Appearance: Colorless gel
Signal Word: WARNING

Statement of Hazard: May cause allergic skin reaction.

**Additional Hazard Information:** 

Short Term: Active ingredient may be harmful if swallowed. May cause eye irritation. May cause mild skin

irritation (based on animal data).

Known Clinical Effects: Individuals sensitive to this material or other materials in its chemical class may develop

allergic reactions. Clinical use of this drug has caused sore throat, fever gastrointestinal disturbances, abnormal liver function tests, kidney dysfunction. Pseudomembranous colitis (manifested by watery diarrhea, urge to defecate, abdominal cramps, low-grade fever, bloody

stools, and abdominal pain) may also occur.

EU Indication of danger: Irritant

**EU Hazard Symbols:** 



**EU Risk Phrases:** 

Australian Hazard Classification (NOHSC):

R43 - May cause sensitization by skin contact. Hazardous Substance. Non-Dangerous Goods.

**Note:** This document has been prepared in accordance with standards for workplace safety, which

require the inclusion of all known hazards of the active substance or its intermediates regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your

workplace.

Material Name: Clindamycin Phosphate Topical Gel

Revision date: 08-Sep-2010 Version: 2.0

### 2. HAZARDS IDENTIFICATION

# 3. COMPOSITION/INFORMATION ON INGREDIENTS

#### **Hazardous**

Ingredient	CAS Number	<b>EU EINECS/ELINCS List</b>	<b>EU Classification</b>	%
Clindamycin Phosphate	24729-96-2	246-433-0	Xi;R36-43 Xn;R22	1
Propylene glycol	57-55-6	200-338-0	Not Listed	*

Ingredient	CAS Number	<b>EU EINECS/ELINCS List</b>	<b>EU Classification</b>	%
Carbomer	54182-57-9	Not Listed	Not Listed	*
Methylparaben	99-76-3	202-785-7	Not Listed	*
Allantoin	97-59-6	202-592-8	Not Listed	*
Water, purified	7732-18-5	231-791-2	Not Listed	*
Polyethylene glycol 400	25322-68-3	Not Listed	Not Listed	*

Additional Information: \* Proprietary

Ingredient(s) indicated as hazardous have been assessed under standards for workplace

Page 2 of 7

safety.

For the full text of the R phrases mentioned in this Section, see Section 16

### 4. FIRST AID MEASURES

Eye Contact: Flush with water while holding eyelids open for at least 15 minutes. If irritation occurs or

persists, get medical attention.

**Skin Contact:** Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek

medical attention.

**Ingestion:** Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not

induce vomiting unless directed by medical personnel. Seek medical attention immediately.

**Inhalation:** Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Symptoms and Effects of Exposure: For information on potential signs and symptoms of exposure, See Section 2 - Hazards

Identification and/or Section 11 - Toxicological Information.

# 5. FIRE FIGHTING MEASURES

**Extinguishing Media:** Use carbon dioxide, dry chemical, or water spray.

Hazardous Combustion Products: Emits toxic fumes of carbon monoxide, carbon dioxide, nitrogen oxides, sulfur oxides and other

sulfur-containing compounds.

Fire Fighting Procedures: During all fire fighting activities, wear appropriate protective equipment, including self-

contained breathing apparatus.

Fire / Explosion Hazards: Not applicable

\_\_\_\_\_

Material Name: Clindamycin Phosphate Topical Gel Page 3 of 7 Revision date: 08-Sep-2010 Version: 2.0

### 6. ACCIDENTAL RELEASE MEASURES

**Health and Safety Precautions:** Personnel involved in clean-up should wear appropriate personal protective equipment (see

Section 8). Minimize exposure.

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill

area thoroughly.

**Measures for Environmental** 

**Protections:** 

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to

avoid environmental release.

**Additional Consideration for Large** 

Spills:

Non-essential personnel should be evacuated from affected area. Report emergency

situations immediately. Clean up operations should only be undertaken by trained personnel.

### 7. HANDLING AND STORAGE

**General Handling:** Avoid breathing vapor or mist. Avoid contact with eyes, skin and clothing. When handling, use

appropriate personal protective equipment (see Section 8). Wash hands and any exposed skin after removal of PPE. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or

other equivalent controls.

Store as directed by product packaging. **Storage Conditions:** 

### 8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Refer to available public information for specific member state Occupational Exposure Limits.

**Clindamycin Phosphate** 

Pfizer OEL TWA-8 Hr: 100µg/m<sup>3</sup>

Propylene glycol

**Australia TWA** 10 mg/m<sup>3</sup> 150 ppm

474 mg/m<sup>3</sup>

**Ireland OEL - TWAs** Listed Latvia OEL - TWA Listed Lithuania OEL - TWA Listed

Polyethylene glycol 400

**Austria OEL - MAKs** Listed Germany - TRGS 900 - TWAs 1000 mg/m<sup>3</sup> Germany (DFG) - MAK 1000 mg/m<sup>3</sup> MAK

Slovenia OEL - TWA Listed

The exposure limit(s) listed for solid components are only relevant if dust or mist may be generated.

Analytical method available for clindamyin. Contact Pfizer Inc for further information. **Analytical Method:** 

**Engineering Controls:** Engineering controls should be used as the primary means to control exposures. General

room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne

contamination levels below the exposure limits listed above in this section.

**Environmental Exposure Controls:** Refer to specific Member State legislation for requirements under Community environmental

legislation.

**Personal Protective Equipment:** Refer to applicable national standards and regulations in the selection and use of personal

protective equipment (PPE).

Material Name: Clindamycin Phosphate Topical Gel Page 4 of 7
Revision date: 08-Sep-2010 Version: 2.0

### 8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Hands: Impervious gloves are recommended if skin contact with drug product is possible and for bulk

processing operations.

**Eyes:** Wear safety glasses or goggles if eye contact is possible.

Skin: Impervious protective clothing is recommended if skin contact with drug product is possible and

for bulk processing operations.

Respiratory protection: Not required for the normal use of this product. If the applicable Occupational Exposure Limit

(OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control

exposures to below the OEL.

# 9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Gel Color: Clear, colorless

Molecular Formula: Mixture Molecular Weight: Mixture

# 10. STABILITY AND REACTIVITY

Chemical Stability: Stable at normal conditions

Conditions to Avoid: None known

Incompatible Materials: As a precautionary measure, keep away from strong oxidizers

### 11. TOXICOLOGICAL INFORMATION

General Information: The information included in this section describes the potential hazards of the individual

ingredients.

# Acute Toxicity: (Species, Route, End Point, Dose)

### **Clindamycin Phosphate**

Rat Oral LD 50 1832 mg/kg

Rat Para-periosteal LD 50 321 mg/kg Rat Intraperitoneal LD 50 745 mg/kg Mouse Oral LD 50 2359 mg/kg Mouse Intravenous LD 50 820 mg/kg

#### Propylene glycol

Mouse Oral LD50 22,000 mg/kg Rat Oral LD50 20,000 mg/kg Rabbit Dermal LD50 20,800 mg/kg

Methylparaben

Mouse Oral LD50 > 8000 mg/kg

Rat Oral LD50 2280 mg/kg

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable

at the highest dose used in the test.

# Irritation / Sensitization: (Study Type, Species, Severity)

#### Clindamycin Phosphate

Page 5 of 7

Material Name: Clindamycin Phosphate Topical Gel

Revision date: 08-Sep-2010 Version: 2.0

### 11. TOXICOLOGICAL INFORMATION

Eye Irritation Rabbit Moderate Skin Irritation Rabbit Mild

### Polyethylene glycol 400

Rabbit Eye Irritation Mild Skin Irritation Rabbit Mild

#### Propylene glycol

Skin Irritation Mild Rabbit Eve Irritation Mild Rabbit

### Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

#### Clindamycin Phosphate

6 Month(s) Rat Oral 600 mg/kg/day NOAEL No effects at maximum dose Oral 600 mg/kg/day 6 Month(s) NOAEL Gastrointestinal system Dog

### Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

### Clindamycin Phosphate

Prenatal & Postnatal Development Rat Subcutaneous 250 mg/kg NOAEL Not teratogenic Prenatal & Postnatal Development Rat Oral 300 mg/kg/day NOAEL Not Teratogenic Prenatal & Postnatal Development Mouse Oral 600 mg/kg/day NOAEL Not Teratogenic Prenatal & Postnatal Development Rabbit Subcutaneous 5 mg/kg/day NOAEL Not Teratogenic, Maternal Toxicity

Reproductive & Fertility Rat Oral 300 mg/kg/day NOAEL No effects at maximum dose

### Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

### Clindamycin Phosphate

Bacterial Mutagenicity (Ames) Salmonella Negative

In Vitro Micronucleus Negative

None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA. Carcinogen Status:

### 12. ECOLOGICAL INFORMATION

**Environmental Overview:** Environmental properties have not been thoroughly investigated. Releases to the environment

should be avoided.

### 13. DISPOSAL CONSIDERATIONS

**Waste Treatment Methods:** Dispose of waste in accordance with all applicable laws and regulations. Member State

specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

# 14. TRANSPORT INFORMATION

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

Page 6 of 7

Material Name: Clindamycin Phosphate Topical Gel

Revision date: 08-Sep-2010 Version: 2.0

### 14. TRANSPORT INFORMATION

# 15. REGULATORY INFORMATION

EU Symbol: Xi EU Indication of danger: Irritant

**EU Risk Phrases:** 

R43 - May cause sensitization by skin contact.

**EU Safety Phrases:** 

S24 - Avoid contact with skin.

S36/37 - Wear suitable protective clothing and gloves.

**OSHA Label:** 

**WARNING** 

May cause allergic skin reaction.

### Canada - WHMIS: Classifications

WHMIS hazard class:

Class D, Division 2, Subdivision B



**Clindamycin Phosphate** 

EU EINECS/ELINCS List 246-433-0

Methylparaben

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

EU EINECS/ELINCS List

202-785-7

**Allantoin** 

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

EU EINECS/ELINCS List

202-592-8

Propylene glycol

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

EU EINECS/ELINCS List

200-338-0

Water, purified

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

Listed

Present

Material Name: Clindamycin Phosphate Topical Gel Page 7 of 7
Revision date: 08-Sep-2010 Version: 2.0

·

15. REGULATORY INFORMATION

REACH - Annex IV - Exemptions from the

obligations of Register:

EU EINECS/ELINCS List 231-791-2

Polyethylene glycol 400

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

Listed

# 16. OTHER INFORMATION

### Text of R phrases mentioned in Section 3

R22 - Harmful if swallowed.

R43 - May cause sensitization by skin contact.

**Data Sources:** Pfizer proprietary drug development information. Safety data sheets for individual ingredients.

Reasons for Revision: Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on

Ingredients. Updated Section 4 - First Aid Measures. Updated Section 7 - Handling and Storage. Updated Section 8 - Exposure Controls / Personal Protection. Updated Section 13 -

Disposal Considerations. Updated Section 15 - Regulatory Information.

Prepared by: Product Stewardship Hazard Communications

Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

**End of Safety Data Sheet** 

\_\_\_\_\_